UPMC-Shadyside Hospital Pittsburgh Vascular Institute — Pittsburgh, Pennsylvania

UPMC-Shadyside Hospital Pittsburgh Vascular Institute is a clinical research site located in Pittsburgh, Pennsylvania, United States 15232.

Crixeo Clinical Trials Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.

UPMC-Shadyside Hospital Pittsburgh Vascular Institute has participated in 1 clinical trials.

Therapeutic areas: Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis.

Sponsors: Boston Scientific Corporation.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Pittsburgh

Browse all research sites in Pennsylvania · View every site in Pittsburgh

Sponsor Feasibility Report

Trust Score: 80/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UPMC-Shadyside Hospital Pittsburgh Vascular Institute?

UPMC-Shadyside Hospital Pittsburgh Vascular Institute has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UPMC-Shadyside Hospital Pittsburgh Vascular Institute conducted?

UPMC-Shadyside Hospital Pittsburgh Vascular Institute has 1 clinical trials on record. Their work covers Carotid Artery Diseases, Stroke, Cerebral Arteriosclerosis.

Is UPMC-Shadyside Hospital Pittsburgh Vascular Institute accredited by Crixeo Clinical Trials?

UPMC-Shadyside Hospital Pittsburgh Vascular Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UPMC-Shadyside Hospital Pittsburgh Vascular Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.